SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud by Block & Leviton LLP; August 10 Deadline To Seek To Serve As Lead Plaintiff

Block & Leviton LLP filed a class action lawsuit against Erasca, Inc. and its executives for allegedly making false and misleading statements about its oncology drug candidate ERAS-0015 between January 2025 and April 2026. The company allegedly touted the drug as 'best-in-class' with superior results compared to a competitor's drug while failing to disclose improper comparisons and patent disputes. Following disclosures of patent infringement accusations and clinical data showing a patient death, Erasca's stock fell over 45%. Investors who purchased stock during the class period may seek damages.